Keywords: AstraZeneca, Financial results, Third-quarter 2012

AstraZeneca 3rd-qtr 2012 takes heavy hit from generics

Article | 25 October 2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) revealed this morning that group sales for the third quarter of 2012 were $6.68 billion, down 15% ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

AstraZeneca

Go to company listing